Pfizer Inc said on Monday annual revenue from its mRNA vaccine portfolio could reach $10 billion to $15 billion by 2030, alleviating fears of a sharp hit to its topline from an expected decline in COVID vaccine demand and patent expirations.
, Pfizer had raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion.
Pfizer expects to lose $17 billion in annual sales between 2025 and 2030 due to the patent expirations, Chief Commercial Officer Angela Hwang said in an investor presentation, where the company provided revenue expectations for its drugs and vaccines.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
S.F. clothing resale software startup Archive raises $15 million Series AThis startup works with brands like Northface to establish used clothing marketplaces.
Consulte Mais informação »
12 Gifts Under $15 That Won't Make You Feel CheapFrom the perfect candle to snarky stickers to witchy accoutrements, these ideas will help you stretch whatever's left of your holiday budget.
Consulte Mais informação »
Colorado to receive over $150 million in opioid funds from $10 billion national CVS, Walgreens settlementColorado is expected to get over $150 million from a multi-billion-dollar national settlement with drug store companies CVS and Walgreens for their roles in the opioid crisis.
Consulte Mais informação »
Bitcoin miner TeraWulf ups hashrate guidance by 16%, raises $10 million as shares plummetTeraWulf negotiated a deal with Bitmain allowing it to expand its hashrate further by early 2023.
Consulte Mais informação »
CVS, Walgreens Finalize $10 Billion in Settlements Over OpioidsCVS and Walgreens have agreed to a combined $10.7 billion to settle allegations they failed to adequately oversee opioid prescriptions, thus contributing to America’s addiction crisis.
Consulte Mais informação »